What does Preamble of BINSA Act do?

This bill proposes to amend title VIII of the Defense Production Act of 1950. The proposed amendment aims to alter the definitions of 'prohibited technology' and 'notifiable technology'.

What does SHORT TITLE. of BINSA Act do?

This bill is formally titled Biotech Investment National Security Act of 2026.

What does FINDINGS. of BINSA Act do?

This section outlines findings related to China's strategy to dominate the global biotechnology industry. It states that U.S. capital investments are accelerating China's acquisition of pharmaceutical intellectual property and clinical development capabilities. Cross-border licensing transactions between U.S./European companies and Chinese firms totaled approximately $136 billion in 2025. Biotechnology is identified as having dual-use applications and presenting strategic dependency risks similar to semiconductors and artificial intelligence. The BIOSECURE Act, part of the National Defense Authorization Act for Fiscal Year 2026, recognized biotechnology as both a national security asset and a vulnerability. The section concludes that outbound investment screening for biotechnology is necessary to prevent long-term strategic dependency risks.

What does AMENDMENTS. of BINSA Act do?

This section amends Section 809 of the Defense Production Act of 1950. The amendments add a definition of 'Biotechnology' to paragraphs (10)(A), (7)(A), and (4)(A). The definition of 'Biotechnology' includes research, development, manufacturing, or commercialization of pharmaceutical products, biological products, and therapeutic compounds. The definition of 'pharmaceutical products' refers to the meaning of 'drug' in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act. The definition of 'biological products' refers to the definition in section 351(i) of the Public Health Service Act. Paragraph (4)(A) is amended to include 'licensing a prohibited technology from a covered foreign person' as an element.

What does RULEMAKING. of BINSA Act do?

This section requires the Secretary of the Treasury to issue a rule defining "biotechnology" within the context of the Defense Production Act of 1950, as amended by this Act. The rule must be issued within one year of the Act's enactment. The Secretary of the Treasury must consult with the Secretaries of Health and Human Services and Defense, and the Director of National Intelligence during the rule-making process. The rule must consider transactions involving intellectual property licensing, drug discovery platforms, clinical research and development, and biologics manufacturing. Priority consideration should be given to licensing transactions, joint ventures, and equity investments related to drug discovery, clinical development, and biologics manufacturing. The rule must consider the potential transfer of pharmaceutical innovation capacity to entities controlled by the People's Republic of China. The defined biotechnology sector should include research, development, manufacturing, and commercialization of pharmaceutical, biological, and therapeutic products. The rule should exclude agricultural biotechnology, industrial fermentation unrelated to pharmaceutical production, and basic academic research.

What does REPORT REQUIRED. of BINSA Act do?

This section requires the Secretary of Defense to submit a report to specified congressional committees. The report must assess whether flows of U.S. capital into China's biotechnology sector negatively affect U.S. national security and military readiness. The report is due within 60 days of the Act's enactment. The report should be submitted in unclassified form, but may include a classified annex. The 'appropriate congressional committees' are defined as several committees from both the House and Senate, including Armed Services, Financial Services/Banking, Intelligence, and committees focused on strategic competition with China.

Back to bills

BINSA Act

Last updated: 6/2/2026 · Introduced: 6/2/2026

Author: John Moolenaar (R-MI)

TL;DR (AI)

This bill amends the Defense Production Act of 1950 to define 'biotechnology' as encompassing research, development, manufacturing, or commercialization of pharmaceutical, biological, and therapeutic products.
It mandates the Secretary of the Treasury to create a rule within one year, defining 'biotechnology' for purposes of the Act, considering transactions like intellectual property licensing and investments related to drug development.
The Secretary of Defense must report within 60 days on whether U.S. capital flows into China's biotechnology sector harm U.S. national security and military readiness.

119th Congressin committeeOfficial page

Verified Votes

No verified votes yet.

Community Votes

No community votes yet. Be the first!

Voting as guest · Sign in for verified votes

Other Sections

Includes provisions on preamble, short title., and 4 more.

6 sections

Click "Show details" to explore individual sections. Use the community vote above or visit All Sections to vote per section.

Read official text

Want the full experience?

Create a free account to cast verified votes on each section, get a personalized summary, and track your voting history.

Create Free Account